1,272 results on '"Yoon, Dok-Hyun"'
Search Results
102. A Patient With CD20-positive T-cell Lymphoma Concurrently Exhibiting B-cell Neoplasm-related Genetic Abnormalities Shows Clonal Escape Post CD20-targeting Treatment
103. Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
104. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
105. Poster: ABCL-088 Subgroup Analysis in RE-MIND2: An Observational, Retrospective Cohort Study of Tafasitamab + Lenalidomide Versus Systemic Therapies in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
106. Extra copy number of BCL2 is correlated with increased BCL-2 protein expression and poor survival in diffuse large B-cell lymphoma treated with chemoimmunotherapy
107. P-002: Clinical outcomes and effectiveness of heart transplantation in patients with systemic light-chain cardiac amyloidosis
108. Electrophysiologic features of POEMS syndrome compared with MGUS‐related neuropathy
109. RGS1 expression is associated with poor prognosis in multiple myeloma
110. Salvage Esophagectomy for Locoregional Failure After Chemoradiotherapy in Patients With Advanced Esophageal Cancer
111. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial
112. Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified
113. Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study
114. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer
115. Translation and validation of Korean Functional Assessment of Cancer Therapy-Esophageal (FACT-E) scale with squamous cell carcinoma and chemoradiation-only patients
116. Phase I study: safety and efficacy of ex vivo-expanded allogeneic natural killer cells (MG4101) with rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
117. Clinical Outcomes and Effectiveness of Heart Transplantation in Patients With Systemic Light-chain Cardiac Amyloidosis
118. Abstract CT127: Trial in progress: A phase II, open-label, multicenter study of capivasertib, a potent, oral pan-AKT inhibitor in patients with relapsed or refractory B-cell non-hodgkin lymphoma (CAPITAL)
119. Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
120. CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.
121. A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma.
122. Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
123. Clinical outcomes of early-progressed follicular lymphoma in Korea: a multicenter, retrospective analysis
124. Distinct genetic alterations in Burkitt-like lymphoma with 11q aberration and Burkitt lymphoma: a novel case report of composite lymphoma
125. Comparison of clinical and laboratory characteristics of nonsecretory multiple myeloma and secretory multiple myeloma in a tertiary care hospital
126. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
127. Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience
128. Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study
129. Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma
130. Clinical significance of the appearance of abnormal protein band in patients with multiple myeloma
131. Phase I Study of Ex Vivo-Expanded Allogeneic Natural Killer Cells (MG4101) with Rituximab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
132. Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea
133. Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
134. TEMPO: A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non Hodgkin Lymphoma (iNHL)
135. A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies
136. Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
137. TCL1 expression predicts overall survival in patients with mantle cell lymphoma
138. Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkinʼs lymphoma: Correlation with MET expression
139. Phase 2 Study of Dovitinib in Patients With Metastatic or Unresectable Adenoid Cystic Carcinoma
140. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis
141. Changing trend of Epstein-Barr virus association in Hodgkin lymphoma in the Republic of Korea
142. 18F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase
143. The role of 18F-fluorodeoxyglucose positron emission tomography at response assessment after autologous stem cell transplantation in T-cell non-Hodgkin’s lymphoma patients
144. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study
145. Blastic plasmacytoid dendritic cell neoplasm: a single-center experience
146. High-dose chemotherapy and autologous stem-cell transplantation in Korean patients with relapsed or refractory Hodgkin lymphoma
147. Prognostic implications of tumor extent in early-stage diffuse large B-cell lymphoma
148. Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy
149. Screening Tests for Early Diagnosis of Multiple Myeloma and Related Plasma Cell Disorders
150. P-118: Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.